logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Cytomegalovirus Infections

    Medications for Cytomegalovirus Infections

    FiltersReset Filters
    5 results

    • ganciclovir sodium

      (ganciclovir sodium)
      Slate Run Pharmaceuticals, LLC
      Usage: Ganciclovir for Injection is indicated for treating cytomegalovirus (CMV) retinitis in immunocompromised adults, including those with AIDS, and for preventing CMV disease in at-risk adult transplant recipients.

    • livtencity

      (MARIBAVIR)
      Takeda Pharmaceuticals America, Inc.
      Usage: LIVTENCITY is indicated for treating post-transplant cytomegalovirus (CMV) infection/disease in adults and pediatric patients (ages 12 and older, weighing at least 35 kg) that is refractory to prior treatment with ganciclovir, valganciclovir, cidofovir, or foscarnet.

    • prevymis

      (LETERMOVIR)
      Merck Sharp & Dohme LLC
      Usage: PREVYMIS® is indicated for the prophylaxis of cytomegalovirus (CMV) infection and disease in CMV-seropositive adult and pediatric patients aged 6 months or older after hematopoietic stem cell transplant, and in high-risk kidney transplant recipients aged 12 years or older who are CMV-seronegative.

    • valcyte

      (valganciclovir)
      H2-Pharma, LLC
      Usage: VALCYTE is indicated for the treatment of cytomegalovirus (CMV) retinitis in adults with AIDS and for the prevention of CMV disease in high-risk kidney and heart transplant patients. It is also used in pediatric patients (4 months to 16 years) for preventing CMV disease post-kidney or heart transplant.

    • valganciclovir hydrochloride

      (Valganciclovir hydrochloride)
      Ajanta Pharma USA Inc.
      Usage: Valganciclovir is indicated for treating cytomegalovirus (CMV) retinitis in AIDS patients and for preventing CMV disease in high-risk transplant recipients (adults and pediatric patients) including kidney and heart transplants.